Nvidia, ByteDance, and the U.S.-China AI Chip Standoff Over H200 Exports 
Oil Prices Slide on US-Iran Talks, Dollar Strength and Profit-Taking Pressure 
Japanese Pharmaceutical Stocks Slide as TrumpRx.gov Launch Sparks Market Concerns 
Iran–U.S. Nuclear Talks in Oman Face Major Hurdles Amid Rising Regional Tensions 
U.S. Eases Venezuela Oil Sanctions to Boost American Investment After Maduro Ouster 
RBI Holds Repo Rate at 5.25% as India’s Growth Outlook Strengthens After U.S. Trade Deal 
Trump Administration Sued Over Suspension of Critical Hudson River Tunnel Funding 
Dollar Near Two-Week High as Stock Rout, AI Concerns and Global Events Drive Market Volatility 
New York Legalizes Medical Aid in Dying for Terminally Ill Patients 
Vietnam’s Trade Surplus With US Jumps as Exports Surge and China Imports Hit Record 
Trump Lifts 25% Tariff on Indian Goods in Strategic U.S.–India Trade and Energy Deal 
Trump to Announce New Federal Reserve Chair Pick as Powell Replacement Looms 
Trump Signs Executive Order Threatening 25% Tariffs on Countries Trading With Iran 
U.S. Stock Futures Slide as Tech Rout Deepens on Amazon Capex Shock 
Fed Governor Lisa Cook Warns Inflation Risks Remain as Rates Stay Steady 
India–U.S. Interim Trade Pact Cuts Auto Tariffs but Leaves Tesla Out 
RFK Jr. Overhauls Federal Autism Panel, Sparking Medical Community Backlash 
U.S. President Donald Trump announced sweeping new trade tariffs Thursday evening, including a 100% levy on imported pharmaceutical products, marking one of his most aggressive moves to date in reshaping America’s trade policy. The new tariffs, set to take effect October 1, will also include a 25% duty on heavy truck imports, 50% on kitchen and bathroom fittings, and 30% on upholstered furniture.
According to Trump, the pharmaceutical tariffs will apply to all branded or patented products, though companies actively building manufacturing plants in the United States will be exempt. He specified that firms must have already broken ground or begun construction on U.S. facilities to qualify. Trump framed the move as a matter of national security and a necessary step to reduce dependency on foreign drug imports.
The United States imported over $212 billion worth of pharmaceutical products in 2024, government data shows. Trump has long criticized this reliance, arguing that it threatens U.S. security and weakens domestic industries. Earlier this year, he demanded that 17 major drugmakers lower domestic drug prices while raising them abroad to balance profits. In August, Trump warned he could hike tariffs as high as 250%, signaling the seriousness of his push for reshoring production.
The tariff threats have already spurred huge investment pledges from global pharma companies. Roche committed to investing $50 billion, while Novartis announced $23 billion in U.S. facilities. American firms including Johnson & Johnson (NYSE:JNJ) and Eli Lilly and Company (NYSE:LLY) are also ramping up domestic operations to hedge against the new trade policies.
These tariffs extend beyond pharmaceuticals, targeting industries like heavy trucks, fittings, and furniture—sectors Trump says need protection to revive U.S. manufacturing and safeguard jobs. While the full impact of these measures on trade partners remains unclear, they underscore the administration’s continued reliance on tariffs as a core tool in its economic agenda.
